Events

September 7, 2022 In Events, News

InCarda Presents Additional Phase 2 Data for InRhythm (Orally Inhaled Flecainide) at the 2022 European Society of Cardiology Congress in Barcelona

Phase 2 INSTANT study results demonstrate conversion with inhaled flecainide leads to rapid reduction in ventricular rate and alleviation of atrial fibrillation-related symptoms; the study also demonstrates the potential to reduce healthcare costs related to acute episodes of atrial fibrillation   [caption id="attachment_23407" align="aligncenter" width="1782"] Dr. John...

May 2, 2022 In Events, News

InCarda Presents Phase 2 Safety and Efficacy Data for InRhythm (Orally Inhaled Flecainide) at the 2022 Heart Rhythm Society Conference in San Francisco

[caption id="attachment_23373" align="aligncenter" width="800"] Dr. Chris Dufton, SVP of Clinical Development, answering questions about INSTANT P2 at HRS 2022 in San Francisco.[/caption] Phase 2 INSTANT study results demonstrate rapid and reproducible restoration of normal heart rhythm with symptom resolution and a predictable and favorable safety profile...

January 26, 2022 In Events, News

InCarda Presents Phase 2 Data for InRhythm (Orally Inhaled Flecainide) at the 2022 Atrial Fibrillation Symposium in New York

Phase 2 INSTANT study results demonstrate rapid restoration of normal heart rhythm with a predictable and favorable safety profile for orally inhaled flecainide.   [caption id="attachment_23370" align="aligncenter" width="800"] Meisa Propst, VP of Clinical Operations at InCarda, presented the P2 INSTANT Safety Analysis Poster at the 2022 AF...

April 14, 2021 In Events

Grace Colón Participates on Panel Hosted by Women in Bio (WIB)

YWIB-San Francisco Bay Area: Spring Into STEM–Extraordinary Leaders Transforming the Future of STEM The San Francisco Bay Area Chapter of Young Women In Bio is thrilled to bring together an extraordinary group of leaders at the forefront of science. Join us for an inspiring discussion with...